{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-25-000003","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.054239+00:00","generated_at":"2026-05-28T06:17:24.351996+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Halozyme raises 2025 guidance: rev $1.15-1.225B, adj EBITDA $755-805M, $250M ASR","bullets":["Raises 2025 total revenue guidance to $1,150-$1,225M, representing 16-23% YoY growth from 2024 midpoint.","Raises 2025 adjusted EBITDA guidance to $755-$805M (24-32% YoY) and non-GAAP diluted EPS to $4.95-$5.35 (21-30% YoY).","Announces new $250M accelerated share repurchase (ASR) under existing $750M share repurchase program.","Reiterates 2024 preliminary unaudited guidance: revenue $970-$1,020M, adjusted EBITDA $595-$625M, non-GAAP EPS $4.00-$4.20."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-25-000003","json":"https://secwatch.observer/filing/0001159036-25-000003.json","markdown":"https://secwatch.observer/filing/0001159036-25-000003.md","text":"https://secwatch.observer/filing/0001159036-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000003/0001159036-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903625000003/halo-20250108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:17:24.351996+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}